The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders as an alternative to the likes of Novo Nordisk’s semaglutide (Wegovy/Ozempic) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound).
However, in February 2025, the US Food and Drug Administration (FDA) signalled that the semaglutide and tirzepatide shortage was over.
Go deeper with GlobalData
This month’s cover feature explores what the end of the shortage means for the compounder segment, with pharmacies and outsourcing facilities now obliged to cease production in April and May respectively.
Also in this issue, we look at what pharma can do to manage rising trial costs, which have risen annually since 2014. Be sure to check out our exclusive interview centred on unorthodox funding strategies for ultra-rare therapies.
All this and the latest pharma industry news, comment, and analysis from GlobalData.
Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataYou can also subscribe here to receive email notifications when a new issue is available.
